Literature DB >> 7916698

Synthesis and regulation of trans-mRNA encoding the immunoglobulin epsilon heavy chain.

A Shimizu1, T Honjo.   

Abstract

We have detected an immunoglobulin heavy-chain trans-mRNA of the epsilon class in which the variable region of the human transgenic mu chain is correctly spliced to the first exon of the endogenous mouse epsilon constant region. Together with our previous observations, all the endogenous isotypes that are targets of class switching have proved to be expressed as trans-mRNA. This indicates that immunoglobulin trans-mRNA synthesis is a general mechanism to express a second heavy-chain isotype with the variable region of the transgenic mu chain. Synthesis of epsilon trans-mRNA is regulated in a way similar to the trans-mRNAs of the gamma subclasses or class switching to epsilon, i.e., interleukin-4 can induce the germline transcript of the epsilon constant region, but costimulation with lipopolysaccharide is necessary for epsilon trans-mRNA expression. The amount of epsilon trans-mRNA induced is similar to that of gamma 1 and higher than expected as judged from the rate of class switching to epsilon. All these data are consistent with our previous hypothesis that trans-mRNA is synthesized by a trans-splicing mechanism and that this mechanism is involved in the simultaneous multiple-isotype expression of immunoglobulin in a single B lymphocyte.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7916698     DOI: 10.1096/fasebj.7.1.7916698

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

1.  Alternative trans-splicing of constant and variable exons of a Drosophila axon guidance gene, lola.

Authors:  Takayuki Horiuchi; Edward Giniger; Toshiro Aigaki
Journal:  Genes Dev       Date:  2003-10-01       Impact factor: 11.361

2.  Trans-chromosomal recombination within the Ig heavy chain switch region in B lymphocytes.

Authors:  M Kingzette; H Spieker-Polet; P C Yam; S K Zhai; K L Knight
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

3.  The 5' and 3' splice sites come together via a three dimensional diffusion mechanism.

Authors:  Z Pasman; M A Garcia-Blanco
Journal:  Nucleic Acids Res       Date:  1996-05-01       Impact factor: 16.971

4.  Circular RNAs from transcripts of the rat cytochrome P450 2C24 gene: correlation with exon skipping.

Authors:  P G Zaphiropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

5.  Enhancer-dependent interaction between 5' and 3' splice sites in trans.

Authors:  J P Bruzik; T Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

6.  Germ-line human epsilon heavy chain gene RNA transcripts utilize the full range of alternative 3' splicing seen in productive epsilon mRNA.

Authors:  K Zhang; D Diaz-Sanchez; A Saxon
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

7.  IgA class switch in I alpha exon-deficient mice. Role of germline transcription in class switch recombination.

Authors:  G R Harriman; A Bradley; S Das; P Rogers-Fani; A C Davis
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

8.  Natural trans-splicing in carnitine octanoyltransferase pre-mRNAs in rat liver.

Authors:  C Caudevilla; D Serra; A Miliar; C Codony; G Asins; M Bach; F G Hegardt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

9.  Recognition of Mycobacterium leprae recombinant 18,000 MW epitopes by IgG subclasses in leprosy.

Authors:  R Hussain; B Menz; H M Dockrell; T J Chiang
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

10.  Extensive analysis of D-J-C arrangements allows the identification of different mechanisms enhancing the diversity in sheep T cell receptor beta-chain repertoire.

Authors:  Silvia Di Tommaso; Rachele Antonacci; Salvatrice Ciccarese; Serafina Massari
Journal:  BMC Genomics       Date:  2010-01-04       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.